-
C Allemani, T Matsuda, V Di Carlo, R Harewood, M Matz, M Niksic, A Bonaventure, M Valkov, CJ Johnson, J Esteve, OJ Ogunbiyi, ESG Azevedo, WQ Chen, S Eser, G Engholm, CA Stiller, A Monnereau, RR Woods, O Visser, GH Lim, J Aitken, HK Weir, MP Coleman, and CW Group, Global surveillance of trends in cancer survival 2000 14 (CONCORD 3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population based registries in 71 countries. Lancet, 2018 .39 110125 ): p. 1023 1075
-
JJ Sung, SC Ng, FK Chan, HM Chiu, HS Kim, T Matsuda, SS Ng, JY Lau, S Zheng, S Adler, N Reddy, KG Yeoh, KK Tsoi, JY Ching, EJ Kuipers, L Rabeneck, GP Young, RJ Steele, D Lieberman, KL Goh, and G Asia Pacific Working, An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut, 2015. 64(1): p. 121-32.
-
Statistics adapted from the American Cancer Society's (ACS) publication, Cancer Facts & Figures 2020 and the ACS website (January 2020).
-
SH Wong and J Yu, Gut microbiota in colorectal cancer: mechanisms of action andclinical applications. Nat Rev Gastroenterol Hepatol, 2019. 16(11): p. 690-704.
-
SH Wong, L Zhao, X Zhang, G Nakatsu, J Han, W Xu, X Xiao, TNY Kwong, H Tsoi, WKK Wu, B Zeng, FKL Chan, JJY Sung, H Wei, and J Yu, Gavage of Fecal Samples From Patients With Colorectal Cancer Promotes Intestinal Carcinogenesis in Germ-Free and Conventional Mice. Gastroenterology, 2017. 153(6): p. 1621-1633 e6.
-
G Nakatsu, X Li, H Zhou, J Sheng, SH Wong, WK Wu, SC Ng, H Tsoi, Y Dong, N Zhang, Y He, Q Kang, L Cao, K Wang, J Zhang, Q Liang, J Yu, and JJ Sung, Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun, 2015. 6: p.8727.
-
Z Dai, OO Coker, G Nakatsu, WKK Wu, L Zhao, Z Chen, FKL Chan, K Kristiansen, JJY Sung, SH Wong, and J Yu, Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome, 2018. 6(1): p. 70.
-
J Yu, Q Feng, SH Wong, D Zhang, QY Liang, Y Qin, L Tang, H Zhao, J Stenvang, Y Li, X Wang, X Xu, N Chen, WK Wu, J Al-Aama, HJ Nielsen, P Kiilerich, BA Jensen, TO Yau, Z Lan, H Jia, J Li, L Xiao, TY Lam, SC Ng, AS Cheng, VW Wong, FK Chan, X Xu, H Yang, L Madsen, C Datz, H Tilg, J Wang, N Brunner, K Kristiansen, M Arumugam, JJ Sung, andJ Wang, Metagenomic analysis of faecal microbiome as a tool towards targeted noninvasive biomarkers for colorectal cancer. Gut, 2017. 66(1): p. 70-78.
-
Q Liang, J Chiu, Y Chen, Y Huang, A Higashimori, J Fang, H Brim, H Ashktorab, SC Ng, SSM Ng, S Zheng, FKL Chan, JJY Sung, and J Yu, Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal Cancer. Clin Cancer Res, 2017. 23(8):p. 2061-2070.
-
JQ Liang, T Li, G Nakatsu, YX Chen, TO Yau, E Chu, S Wong, CH Szeto, SC Ng, FKL Chan, JY Fang, JJY Sung, and J Yu, A novel faecal Lachnoclostridium marker for the noninvasive diagnosis of colorectal adenoma and cancer. Gut, 2019.
-
TF Imperiale, DF Ransohoff, SH Itzkowitz, TR Levin, P Lavin, GP Lidgard, DA Ahlquist, and BM Berger. Multitarget Stool DNA Testing for Colorectal-Cancer Screening. The New England Journal of Medicine, 2014.
- US patent Assessing Risk for Colorectal Adenoma Recurrence by Noninvasive Means (1st Provisional Application No. 63/116104, Filing date: 19 Nov 2020); US patent Assessing Risk for Colorectal Adenoma Recurrence by Noninvasive Means (2nd Provisional Application No. 63/196582, Filing date: 3 Jun 2021)
M3CRC™（〝該檢測〞）不是診斷檢測。該檢測的檢測結果應謹慎解讀。〝低〞至〝中〞度的結直腸腺瘤風險和〝低〞度的結直腸癌風險的檢測結果不能保證結直腸腺瘤和/或結直腸癌不存在。〝中高〞度或以上的結直腸腺瘤風險和〝中〞度或以上的結直腸癌風險的檢測結果不能保證結直腸腺瘤和/或結直腸癌存在。〝低〞度的復發風險不能保證結直腸腺瘤和/或結直腸癌不會復發。〝高〞度的復發風險不能保證結直腸腺瘤和/或結直腸癌會復發。暫時尚未確定應每隔多久重複接受該檢測。本小冊子上的資料僅供參考， 它不能代替醫生或專業醫護人員的建議。 如果你對以上資訊有任何疑問，請諮詢你的醫生。
.jpg)
